22.86
前日終値:
$22.10
開ける:
$22.12
24時間の取引高:
771.88K
Relative Volume:
0.87
時価総額:
$939.55M
収益:
$681.75M
当期純損益:
$70.47M
株価収益率:
15.77
EPS:
1.45
ネットキャッシュフロー:
$173.19M
1週間 パフォーマンス:
-2.56%
1か月 パフォーマンス:
+10.54%
6か月 パフォーマンス:
-14.48%
1年 パフォーマンス:
-2.85%
Pacira Biosciences Inc Stock (PCRX) Company Profile
名前
Pacira Biosciences Inc
セクター
電話
650-242-8052
住所
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
PCRX
Pacira Biosciences Inc
|
22.86 | 908.31M | 681.75M | 70.47M | 173.19M | 1.45 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Equal Weight |
| 2025-11-17 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-25 | アップグレード | Truist | Hold → Buy |
| 2025-01-30 | アップグレード | Truist | Sell → Hold |
| 2024-08-13 | ダウングレード | Truist | Buy → Sell |
| 2024-08-12 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2024-08-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 再開されました | JP Morgan | Overweight |
| 2023-12-20 | 開始されました | Raymond James | Outperform |
| 2023-08-03 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 再開されました | Wedbush | Outperform |
| 2022-10-21 | 再開されました | Jefferies | Buy |
| 2022-01-03 | 再開されました | JP Morgan | Overweight |
| 2021-07-26 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 再開されました | JP Morgan | Neutral |
| 2021-04-09 | 開始されました | Berenberg | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-02-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 繰り返されました | Needham | Buy |
| 2020-05-27 | 開始されました | Guggenheim | Neutral |
| 2020-04-07 | 開始されました | Northland Capital | Outperform |
| 2020-03-20 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-24 | 開始されました | SunTrust | Buy |
| 2020-01-23 | 開始されました | SunTrust | Buy |
| 2019-11-06 | 開始されました | BTIG Research | Buy |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-05-06 | アップグレード | Mizuho | Underperform → Neutral |
| 2019-05-02 | アップグレード | Stifel | Sell → Hold |
| 2019-02-01 | ダウングレード | Mizuho | Neutral → Underperform |
| 2018-08-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-21 | 繰り返されました | Mizuho | Neutral |
| 2018-02-16 | ダウングレード | Needham | Buy → Hold |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2018-01-04 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-01-03 | 開始されました | Leerink Partners | Mkt Perform |
すべてを表示
Pacira Biosciences Inc (PCRX) 最新ニュース
Vanguard Group Inc. Trims Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference - The Manila Times
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Pacira BioSciences (NASDAQ:PCRX) Stock Price Up 4.6%What's Next? - MarketBeat
PCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) - Bitget
Pacira BioSciences (PCRX) Shows Promising Results in Knee Surger - GuruFocus
Pacira BioSciences, Inc. Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry - marketscreener.com
PCRX Earnings History & Surprises | EPS & Revenue Results | PACIRA BIOSCIENCES INC (NASDAQ:PCRX) - ChartMill
Pacira BioSciences (PCRX) Valuation Check After Mixed Share Performance And High P/E Multiple - Sahm
Assessing Pacira BioSciences (PCRX) Valuation After Recent Share Price Weakness - Yahoo Finance
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down - The Globe and Mail
Pacira BioSciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PCRX) 2026-02-27 - Seeking Alpha
Pacira BioSciences (NASDAQ:PCRX) Shares Gap DownWhat's Next? - MarketBeat
Truist Adjusts Price Target on Pacira Biosciences to $27 From $28, Maintains Buy Rating - marketscreener.com
Pacira BioSciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pacira BioSciences Q4 Profit Return Tests Bullish Turnaround Narrative - Sahm
Pacira BioSciences Q4 Earnings Call Highlights - Yahoo Finance
Pacira BioSciences Inc (PCRX) Q4 2025 Earnings Call Highlights: - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Releases Earnings Results, Misses Expectations By $0.28 EPS - MarketBeat
Pacira BioSciences reports fourth quarter and full-year 2025 financial results - marketscreener.com
Pacira Biosciences slips as 2026 revenue guidance, Q4 2025 results disappoint - MSN
Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results - TradingView
Pacira (PCRX) Q4 2025 Earnings Call Transcript - AOL.com
Pacira Biosciences (PCRX) Projects Robust Growth in FY26 with St - GuruFocus
Pacira Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q4 2025 Pacira Biosciences Inc Earnings Call Transcript - GuruFocus
Pacira BioSciences Inc. (PCRX) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Pacira BioSciences Q4 Earnings Assessment - Benzinga
BRIEF-Pacira Biosciences FY Adjusted EBITDA USD 186.5 Million Vs. IBES Estimate USD 204 Million - TradingView
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewswire
Pacira BioSciences, Inc. (PCRX) Stock Analysis: A Healthcare Innovator with 28.58% Potential Upside - DirectorsTalk Interviews
Pacira Biosciences, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Pacira BioSciences, Inc. $PCRX Shares Acquired by Doma Perpetual Capital Management LLC - MarketBeat
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Can Pacira BioSciences Inc expand its profit margins2025 Valuation Update & Detailed Earnings Play Alerts - baoquankhu1.vn
Pacira Biosciences (PCRX) Securities Lawsuit Dismissed by New Jersey Federal Court - TipRanks
Can Pacira BioSciences Inc. stock deliver sustainable ROEQuarterly Profit Review & AI Driven Stock Reports - mfd.ru
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
MSN Money - MSN
Pacira BioSciences (PCRX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
Pacira BioSciences, Inc. (PCRX) Stock Analysis: A Closer Look at Its 36.49% Potential Upside - DirectorsTalk Interviews
Is Pacira BioSciences Inc. trading at a discountEarnings Risk Report & Consistent Profit Trade Alerts - mfd.ru
Understanding Momentum Shifts in (PCRX) - Stock Traders Daily
Will Pacira BioSciences Inc. (82P) stock gain from lower interest ratesWeekly Trade Summary & AI Based Buy/Sell Signal Reports - mfd.ru
Should you avoid Pacira BioSciences Inc. stock right nowLong Setup & AI Enhanced Trading Signals - mfd.ru
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - GuruFocus
Should you avoid Pacira BioSciences Inc stock right nowJuly 2025 Setups & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Pacira BioSciences (PCRX) CEO receives 261,818 stock units award - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pacira Biosciences Inc (PCRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):